Advertisement
Home 2015

Archives

Stroke is the third leading cause of death in women

Awareness of Female-Specific Early Stroke Signs Lacking

0
Pregnancy, migraines, and hormone therapy put women at increased risk
Screening rates for colorectal

CDC: CA Screening Rates Below Healthy People 2020 Targets

0
Includes tests for colorectal, breast, and cervical malignancies
Americans' levels of triglycerides have dropped significantly in the past decade

CDC: Triglyceride Levels Falling for Americans

0
But many people still at risk
The U.S. birth rate remained at an all-time low in 2013

CDC: U.S. Birth Rate Reaches Historic Low

0
Drop in teen birth rate, poor economy explain downward trend
There's not enough data to decide whether or not electronic cigarettes can help smokers quit

USPSTF: Not Enough Data on E-Cigarettes As Cessation Aid

0
More and better data is needed, U.S. Preventive Services Task Force says
Bayer's contraceptive implant Essure can cause serious complications and should be taken off the market

FDA Petitioned to Stop Sales of Essure Implant

0
Reported complications include back and pelvic pain, dislodged coils, heavy prolonged menstrual periods
Issues that will be at the forefront of the National Medical Student Meeting include vaccinations

Five ‘Top Issues’ to Be Discussed at AMA Medical Student Forum

0
Issues include vaccination, Medicaid expansion, health care economics, loans, opioid epidemic
Raplixa (human fibrin sealant) has been approved by the U.S. Food and Drug Administration to help control bleeding during surgery

FDA Approves Raplixa to Help Control Surgical Bleeding

0
Spray-dried fibrin sealant promotes clotting when other methods are 'ineffective or impractical'
The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.

FDA Approves First Generic Abilify

0
For treatment of bipolar disorder or schizophrenia
Kybella (deoxycholic acid) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe submental fat.

FDA Approves Kybella for Reducing Submental Fat

0
Use for fat outside submental area not approved, not recommended